J&J, Other Q1 Financials Beg the Queston: What Does It Mean to Miss Expectations?

Published: Apr 19, 2024 By Greg Slabodkin


Pictured: An illustration of human hands holding up a yellow arrow showing an upward trend/iStock, Cristina Gaidau

This week marked the start of the biopharma earnings season for the first quarter of 2024, with Johnson & Johnson reporting financial results. As I opined in a column two months ago, it’s not my favorite time of the year. My gripe is that biopharma’s quarterly reporting is often predictable, with a low bar for companies to beat Wall Street earnings and revenue estimates. And how fun is that? Well, for investors in those situations I guess it can be.

J&J is always the first out of the gate for earnings season, serving as a bellwether for the industry. The company on Tuesday reported mixed results for Q1 2024 as it beat estimates for…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks